Narrow Results Clear All
Search results for "Drug shortages"
- Drug shortages
Drug Shortages: Certain Factors Are Strongly Associated With This Persistent Public Health Challenge.
Washington, DC: United States Government Accountability Office; July 7, 2016. Publication GAO-16-595.
Despite the reduction of drug shortages in recent years, access to certain types of drugs, such as generic sterile injectable medications, remains limited. Analyzing data on drug shortages in the United States, this government report identifies factors that contribute to shortages and suggests prioritizing efforts to address the most pressing problems including suppliers that fail to comply with standards.
Addressing the Global Shortages of Medicines, and the Safety and Accessibility of Children's Medication.
Geneva, Switzerland: World Health Organization; 2015.
Drug shortages have the ability to affect the patient safety in emergency departments, oncology services, and pediatrics. This report discusses the consequences of drug shortages, approaches different countries are taking to reduce their occurrence, and strategies such as proactive identification of potential supply limitations and collective agreements to manage shortages.
Drug Shortages: Public Health Threat Continues, Despite Efforts to Help Ensure Product Availability.
Washington, DC: United States Government Accountability Office; February 10, 2014. Publication GAO-14-194.
Silver Spring, MD: Food and Drug Administration; October 2013.
This report outlines the FDA's plans to address drug shortages, including streamlining tracking processes and developing early warning signals to identify potential shortages.
Tampa, FL: International Society for Pharmaceutical Engineering; June 2013.
London, UK: All-Party Pharmacy Group; May 2012.
This report discusses the impact of drug shortages in the United Kingdom and describes potential solutions.
Silver Spring, MD: US Food and Drug Administration; October 31, 2011.
This report outlines the complex nature of drug shortages and suggests strategies to augment the FDA's efforts to address them.